Psychedelic drugs are an emerging sector with exciting investment potential. Here are some tips on beginning your due diligence.
Exploring the companies and themes that make up this emerging and exciting new sector
Clarmin Explorations Inc. Enters Into Amalgamation Agreement for Reverse Takeover With Cybin Corp.
Cybin Corp will become the latest psychedelics company to go public, via RTO.
Empower to Open Wellness Clinic in Vancouver, Provides Updates on Its Psychedlics Division Dosed Wellness
Empower's new wellness clinic in Vancouver will support development of its psychedelics division.
Why Psychedelics Micro-Dosing Applications Have The Inside Track On Commercialization
Psychedelics micro-dosing offers several key advantages over psychedelic drug applications centered around heavier dosages.
ATAI Life Sciences Forges Premier Psychedelics R&D Platform
ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.
Top Canadian Entrepreneur Michael Forbes Joins Board of Directors of PharmaDrug Inc.
PharmaDrug adds depth to its board with new Director who has a wealth of healthcare and addiction-therapy experience.
Champignon Announces Closing of $15 Million Bought Deal Private Placement
Champignon Brands closes on a $15 million financing to expand its clinical psychedelics research programs.
Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with University of Wisconsin-Madison
Revive expands on its psychedelics research aimed at addiction treatment.
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.
Will Compass Pathways Be The Next Unicorn?
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
MindMed Begins Phase 2 Clinical Trial of LSD for Treating "Suicide Headaches"
MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.
Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance IP Portfolio
Champignon Brands has added a new contact research organization (CRO) to advance its IP portfolio.